Hormone Replacement Therapy in the Geriatric Patient: Current State of the Evidence and Questions for the Future. Estrogen, Progesterone, Testosterone, and Thyroid Hormone Augmentation in Geriatric Clinical Practice: Part 1

Age Management Institute, 200 West 57 Street, New York, NY 10019, USA.
Clinics in Geriatric Medicine (Impact Factor: 3.19). 11/2011; 27(4):541-59. DOI: 10.1016/j.cger.2011.07.013
Source: PubMed


This article presents an up-to-date review of the literature on hormone augmentation in the elderly to help primary care physicians better evaluate and utilize hormone replacement and optimization strategies to benefit their patients. The scientific literature suggests that hormone supplementation with estrogen, progesterone, testosterone, growth hormone, and thyroid hormone has the potential to improve quality of life and to prevent, or reverse, the many symptoms and conditions associated with aging, including fatigue, depression, weight gain,frailty, osteoporosis, loss of libido, and heart disease. Possible long-term side effects are also considered.

84 Reads
  • Source
    • "Testosterone improves the efficacy of germ cell differentiation and active maturation [33,34]. Recently, testosterone has been used in the clinical treatment of andropause patients with oligozoospermia and maturation arrest of sperms, despite its various side effects [10,11,35,36]. Hence, consistent with previous studies, it can be suggested that the enhanced activity and health of Leydig cells together with the enhanced serum testosterone levels by CRS-10 were the bases of improved spermatogenesis and activation of sperm. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Many aging male suffer various andropause symptoms including loss of physical and mental activities. This study evaluated the putative alleviative effects of CRS-10 dandelion and rooibos extract complex (CRS-10) on the symptoms of andropause. The survival rate of TM3 Leydig cells (TM3 cells) treated with CRS-10 was measured based on typical physiological stress. After daily intake of CRS-10 for 4 weeks, the level of testosterone, physical activity and both the number and activity of sperm in older rats (18 weeks) were measured. Furthermore, thirty males were surveyed with AMS (Aging Males' Symptoms) questionnaire after intake of 400 mg of CRS-10. Overall, CRS-10 protected TM3 cells from serum restriction and oxidative stress via activation of ERK and Akt pathways. The level of testosterone and activation of spermatogenesis in rats were significantly enhanced. In addition, physical locomotion was markedly improved. Daily intake of 400 mg of CRS-10 improved the quality of life among agingmale respondents, according to a clinical survey using the AMS. The results indicate the potential of CRS-10 as a safe and efficacious natural substance for reducing or alleviating andropause symptoms.
    Nutrition research and practice 12/2012; 6(6):505-512. DOI:10.4162/nrp.2012.6.6.505 · 1.44 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Fucoidan extracted from Ecklonia cava had strong anti-inflammatory activities. However, the direct effects of fucoidan of E. cava on anti-inflammatory activities in vivo model remained to be determined. Therefore, the present study was designed to assess in vivo anti-inflammatory effect of fucoidan extracted from E. cava (ECF) using tail-cutting-induced and lipopolysaccharide (LPS)-stimulated zebrafish model. Treating zebrafish model with tail-cutting and LPS-treatment significantly increased the ROS and NO level. However, ECF inhibited this tail-cutting-induced and LPS-stimulated ROS and NO generation. These results show that ECF alleviated inflammation by inhibiting the ROS and NO generation induced by tail-cutting and LPS-treatment. In addition, ECF has a protective effect against the toxicity induced by LPS exposure in zebrafish embryos. This outcome could explain the potential anti-inflammatory activity of ECF, which might have a beneficial effect during the treatment of inflammatory diseases.
    01/2013; 92(1):84-9. DOI:10.1016/j.carbpol.2012.09.066
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Using microarray analysis, we found that aging sarcopenia is associated with a sharp increase in the mRNA of the matricellular protein CCN1 (Cyr61/CTGF/Nov). CCN1 mRNA was up-regulated 113-fold in muscle of aged versus young rats. CCN1 protein was increased in aging muscle in both rats (2.8-fold) and mice (3.8-fold). When muscle progenitor cells (MPCs) were treated with recombinant CCN1, cell proliferation was decreased but there was no change in the myogenic marker myoD. However, the CCN1 treated MPCs did express a senescence marker (SA-╬▓gal). Interestingly, we found CCN1 increased p53, p16(Ink4A) and pRP (hypophosphorylated retinoblastoma protein) protein levels, all of which can arrest cell growth in MPCs. When MPCs were treated with aged rodent serum CCN1 mRNA increased by 7-fold and protein increased by 3-fold suggesting the presence of a circulating regulator. Therefore, we looked for a circulating regulator. Wnt-3a, a stimulator of CCN1 expression, was increased in serum from elderly humans (2.6-fold) and aged rodents (2.0-fold) compared with young controls. We transduced C2C12 myoblasts with wnt-3a and found that CCN1 protein was increased in a time and dose dependent manner. We conclude that in aging muscle, the circulating factor, wnt-3a, acts to increase CCN1 expression, prompting muscle senescence by activating cell arrest proteins.
    AJP Cell Physiology 11/2013; 306(1). DOI:10.1152/ajpcell.00066.2013 · 3.78 Impact Factor
Show more